Literature DB >> 11306728

Hepatotoxicity of chemotherapy.

P D King1, M C Perry.   

Abstract

After assessment of tumor histology, the next important factor to consider in the selection of a chemotherapy regime is organ function. Patients who are to receive chemotherapy require careful assessment of liver function prior to treatment to determine which drugs may not be appropriate, and which drug doses should be modified. Following therapy abnormalities of liver function tests may be due to the therapy rather than to progressive disease, and this distinction is of critical importance. Furthermore, not all abnormalities in liver function are due to the tumor or its treatment, and other processes, such as hepatitis, must be kept in mind. This article reviews the hepatic toxicity of chemotherapeutic agents, and suggests dose modifications based upon liver function abnormalities. Emphasis is placed on agents known to be hepatotoxic, and those agents with hepatic metabolism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11306728     DOI: 10.1634/theoncologist.6-2-162

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  95 in total

Review 1.  [Comorbidity oriented oncology - an overview].

Authors:  Ralph Simanek; Michael Wuensch; Roland Edlinger; Bernhard Hammerl-Ferrari; Ludwig Kramer; Klaus Geissler
Journal:  Wien Klin Wochenschr       Date:  2010-04       Impact factor: 1.704

Review 2.  Liver metastases: Microenvironments and ex-vivo models.

Authors:  Amanda M Clark; Bo Ma; D Lansing Taylor; Linda Griffith; Alan Wells
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-06

3.  Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.

Authors:  Jie Wu; Lei Song; Dan-Yi Zhao; Bing Guo; Jing Liu
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

4.  Premithramycinone G, an early shunt product of the mithramycin biosynthetic pathway accumulated upon inactivation of oxygenase MtmOII.

Authors:  Mohamed S Abdelfattah; Jürgen Rohr
Journal:  Angew Chem Int Ed Engl       Date:  2006-08-25       Impact factor: 15.336

5.  Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases.

Authors:  Mehdi Karoui; Christophe Penna; Mohamed Amin-Hashem; Emmanuel Mitry; Stephane Benoist; Brigitte Franc; Philippe Rougier; Bernard Nordlinger
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

6.  Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment.

Authors:  Muhammad Wasif Saif; Lee Rosen; Michelle A Rudek; Weijing Sun; Dale R Shepard; Carlos Becerra; Fumiaki Yamashita; Paul Bebeau; Robert Winkler
Journal:  Br J Clin Pharmacol       Date:  2019-03-28       Impact factor: 4.335

7.  Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens.

Authors:  Christopher C Denton; Yasmin A Rawlins; Matthew J Oberley; Deepa Bhojwani; Etan Orgel
Journal:  Pediatr Blood Cancer       Date:  2017-12-08       Impact factor: 3.167

8.  Vanadium as a chemoprotectant: effect of vanadium(III)-L-cysteine complex against cyclophosphamide-induced hepatotoxicity and genotoxicity in Swiss albino mice.

Authors:  Abhishek Basu; Arin Bhattacharjee; Somnath Singha Roy; Prosenjit Ghosh; Pramita Chakraborty; Ila Das; Sudin Bhattacharya
Journal:  J Biol Inorg Chem       Date:  2014-04-29       Impact factor: 3.358

9.  Clofarabine and Cytarabine Regimen for Acute Myeloid Leukemia.

Authors:  Kristin V Ho; Dominic A Solimando; J Aubrey Waddell
Journal:  Hosp Pharm       Date:  2015-11-24

10.  Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults.

Authors:  Anne M Muehe; Dan Feng; Rie von Eyben; Sandra Luna-Fineman; Michael P Link; Travis Muthig; Amy E Huddleston; Edward A Neuwelt; Heike E Daldrup-Link
Journal:  Invest Radiol       Date:  2016-04       Impact factor: 6.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.